Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316624 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP2D6CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL6317022 | 0.88 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP2C9CYP2C19TMEM97 | |
| SCHEMBL6317028 | 0.88 | CYP1A2 (0.42) | CYP1A2CYP2D6CYP2C9CYP2C19TMEM97 | |
| SCHEMBL6317869 | 0.81 | PPARA (0.48) | CYP3A4TMEM97SIGMAR1PPARA | |
| SCHEMBL6323037 | 0.80 | ALDH1A1 (0.38) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6323034 | 0.80 | ALDH1A1 (0.38) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6315793 | 0.80 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL6315785 | 0.80 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL6316122 | 0.80 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6316129 | 0.80 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | claimed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | claimed |
| US-6887877-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-05-03 | — | — | US | disclosed |
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | SHIRE BIOCHEM INC. (CA) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229053-A1 | Compounds and methods for the treatment or prevention of flavivirus infections | HAVCR2, ZC3HAV1, MAVS | CYP1A2 514/4885CYP2D6 1300/4885CYP2C9 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.